These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25997544)

  • 1. Comparison of pharmacokinetics and uric acid lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.
    Kim KA; Park JY
    Int J Clin Pharmacol Ther; 2015 Aug; 53(8):667-73. PubMed ID: 25997544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
    Khosravan R; Kukulka MJ; Wu JT; Joseph-Ridge N; Vernillet L
    J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects.
    Khosravan R; Grabowski BA; Wu JT; Joseph-Ridge N; Vernillet L
    Clin Pharmacokinet; 2006; 45(8):821-41. PubMed ID: 16884320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
    Kim KA; Park SJ; Kim C; Park JY
    Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study.
    Ullah MA; Shams-Ud-Dowla ; Maruf AA; Azad MA; Shohag MH; Sultana R; Latif AH; Hasnat A
    Clin Ther; 2010 Jul; 32(7):1419-26. PubMed ID: 20678688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
    Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
    Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence of two intravenous formulations of antithrombin III: a two-way crossover study in healthy Korean subjects.
    Kim KA; Lim YY; Kim SH; Park JY
    Clin Ther; 2013 Nov; 35(11):1752-61. PubMed ID: 24094463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
    Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.
    Grabowski B; Khosravan R; Wu JT; Vernillet L; Lademacher C
    Br J Clin Pharmacol; 2010 Jul; 70(1):57-64. PubMed ID: 20642548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers.
    Parrillo-Campiglia S; Ercoli MC; Umpierrez O; Rodríguez P; Márquez S; Guarneri C; Estevez-Parrillo FT; Laurenz M; Estevez-Carrizo FE
    Clin Ther; 2009 Oct; 31(10):2224-32. PubMed ID: 19922893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.
    Yoon S; Shin D; Lee H; Jang IJ; Yu KS
    Drug Des Devel Ther; 2015; 9():5033-49. PubMed ID: 26357467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and bioequivalence study of three oral formulations of valsartan 160 mg: a single-dose, randomized, open-label, three-period crossover comparison in healthy Indian male volunteers.
    Iqbal M; Khuroo A; Batolar LS; Tandon M; Monif T; Sharma PL
    Clin Ther; 2010 Mar; 32(3):588-96. PubMed ID: 20399995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioequivalence of two levothyroxine tablet formulations without and with mathematical adjustment for basal thyroxine levels in healthy Argentinian volunteers: a single-dose, randomized, open-label, crossover study.
    Di Girolamo G; Keller GA; de Los Santos AR; Schere D; Gonzalez CD
    Clin Ther; 2008 Nov; 30(11):2015-23. PubMed ID: 19108789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study.
    Takai M; Yamauchi T; Ookura M; Matsuda Y; Tai K; Kishi S; Yoshida A; Iwasaki H; Nakamura T; Ueda T
    Anticancer Res; 2014 Dec; 34(12):7287-96. PubMed ID: 25503162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic, tolerability, and bioequivalence comparison of three different intravenous formulations of recombinant human erythropoietin in healthy Korean adult male volunteers: an open-label, randomized-sequence, three-treatment, three-way crossover study.
    Cho SH; Lim HS; Ghim JL; Choe S; Kim UJ; Jung JA; Bae KS
    Clin Ther; 2009 May; 31(5):1046-53. PubMed ID: 19539105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.